{
    "nct_id": "NCT03767335",
    "official_title": "Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy",
    "inclusion_criteria": "* Histologically confirmed invasive adenocarcinoma of the breast\n* Known HER2+ breast cancer\n* Advanced or metastatic breast cancer harbouring PIK3CA mutation on tissue sample\n* > 2 lines of anti-HER2 based regimens with at least 1 regimen with trastuzumab\n* Radiological documented evidence of progressive disease\n* Life expectancy ≥ 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous treatment with PI3K inhibitors\n* Brain metastases untreated, unless treated > 4 weeks and only if clinically stable and not receiving corticosteroids\n* History of clinically significant bowel disease\n* ≥ grade 2 diarrhoea\n* History of significant, uncontrolled, or active cardiovascular disease\n* Any serious and/or unstable pre-existing psychiatric or neurologic illness or other conditions that could interfere with patient's safety\n* Not controlled diabetes mellitus (glycated haemoglobin [HbA1c] >7%) and fasting plasma glucose >126 mg/dL\n* Concurrent chronic treatment with steroids, as immunosuppressant, or another immunosuppressive agent",
    "miscellaneous_criteria": "Main"
}